Tag MAY DAHER

Cytokine Release Syndrome Following CD19 Directed Chimeric Antigen Receptor T-Cell Therapy

Introduction T-cells genetically engineered to express a chimeric antigen receptor (CAR) that targets a specific tumor antigen have become a major clinical tool to treat several high-risk hematologic malignancies. Since the development of the first CAR T-cell in 1989, remarkable…